This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Hims & Hers Stock Jumps 156.9% in Three Months: What's Next?
by Debanjana Dey
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
AHCO or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. ABT: Which Stock Is the Better Value Option?
ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?
by Urmimala Biswas
Abbott projects organic sales growth between 7.5% and 8.5% for 2025.
MDT Stock Trades Cheaper Than Peers Ahead of Q3 Earnings: Time to Buy?
by Urmimala Biswas
Medtronic expects its fiscal 2025 third-quarter revenues to reflect an unfavorable impact of 1% from currency translation.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Hims & Hers Stock Surges 69.2% in Three Months: What's Next?
by Debanjana Dey
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
BSX Pre-Q4 Earnings: To Buy or Not to Buy Boston Scientific Stock Now?
by Urmimala Biswas
Boston Scientific is expected to have registered strong growth in the Asia Pacific in the fourth quarter, led by strength in China and Japan.
SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans
by Zacks Equity Research
SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Reasons to Retain ABT Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.
The Zacks Analyst Blog Highlights Cisco Systems, Abbott Laboratories and Coca-Cola
by Zacks Equity Research
Cisco Systems, Abbott Laboratories and Coca-Cola are part of the Zacks top Analyst Blog.
Expanding EPD Business Supports ABT Stock Amid Macro Issues
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Top Stock Reports for Cisco, Abbott & Coca-Cola
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), Abbott Laboratories (ABT) and The Coca-Cola Company (KO).
BD Stock Rises on Biosero Deal for AI-Powered Robotic Cytometry Tech
by Zacks Equity Research
BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.
TMDX Stock Plunges 49.2% in Three Months: What's Behind the Downfall?
by Debanjana Dey
TransMedics is navigating macroeconomic challenges amid its focus on meaningful progress across each of its growth initiatives.
TEM Stock Rises on Launch of AI-Powered Health Concierge App
by Zacks Equity Research
Tempus AI announces the launch of olivia, an AI-enabled personal health concierge app designed to revolutionize patient care and engagement nationwide.
Here's Why you Should Add Nevro Stock to Your Portfolio Now
by Zacks Equity Research
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.
Reasons to Hold Avanos Medical Stock in Your Portfolio Now
by Zacks Equity Research
AVNS' strong product line and focus on R&D raise optimism about the stock.
Here's Why You Should Add Surmodics Stock to Your Portfolio Now
by Zacks Equity Research
SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
by Zacks Equity Research
ABT delivers a strong underlying base business performance for the fourth quarter of 2024.
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
GEHC Stock Gains on the Collaborated Launch of Care Innovation Hub
by Zacks Equity Research
GE HealthCare announces the launch of a Care Innovation Hub, a joint research collaboration with the University of California, San Francisco.
Compared to Estimates, Abbott (ABT) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Abbott (ABT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.